1. Injectable Hydrogel of Chitosan-Octyl Itaconate Conjugate Modulates Inflammatory Response.
- Author
-
Zhou S, He J, Liu Q, Chen T, Guan X, Gao H, Jiang J, Wang J, Peng X, and Wu J
- Subjects
- Animals, Rats, Male, Rats, Sprague-Dawley, Mice, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents administration & dosage, Chitosan chemistry, Succinates chemistry, Succinates pharmacology, Hydrogels chemistry, Hydrogels pharmacology, Inflammation drug therapy, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents administration & dosage
- Abstract
Itaconic acid and its derivative 4-octyl itaconate (OI) represent a novel anti-inflammatory medication that has demonstrated efficacy in multiple inflammation models because of its minimal side effects. Recently, natural polymers conjugated with small molecule drugs, known as polymer-drug conjugates (PDCs), have emerged as a promising approach to sustained drug release. In this work, we reported an approach to prepare a PDC containing an OI and make it into an injectable hydrogel. Chitosan (CS) was selected for PDC synthesis because of its abundant free amino groups that can be conjugated with molecules containing carboxyl groups by carbodiimide chemistry. We used an ethanol/water cosolvent system to synthesize a CS-OI conjugate via EDC/NHS catalysis. The CS-OI conjugate had improved water solubility and unique anti-inflammatory activity and did not show compromised antibacterial activity compared with unmodified CS. Beta-glycerophosphate (β-GP) cross-linked CS-OI hydrogel exhibited good injectability with sustainable OI release and effectively modulated inflammatory response in a rat model. Therefore, this study provides valuable insights into the design of PDC hydrogels with inflammatory modulatory properties.
- Published
- 2024
- Full Text
- View/download PDF